De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo

Blood

Volumn 100, Issue 4, 2002, Pages 1240-1247

  Dervieux, Thierry ^a,b   Brenner, Timothy L ^a,b   Hon, Yuen Y ^a,b   Zhou, Yinmei ^a,b   Hancock, Michael L ^a,b   Sandlund, John T ^a,b   Rivera, Gaston K ^a,b   Ribeiro, Raul C ^a,b   Boyett, James M ^a,b   Pui, Ching Hon ^a,b   Relling, Mary V ^a,b   Evans, William E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; RASBURICASE; URICOZYME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CELL LINEAGE; CHILD; CONTROLLED STUDY; DNA SYNTHESIS; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERURICEMIA; IMMUNOPHENOTYPING; IN VIVO STUDY; INFANT; INHIBITION KINETICS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PURINE SYNTHESIS; T LYMPHOCYTE;

EID: 0037103310     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0495     Document Type: Article

References (31)

1. Acute lymphoblastic leukemia
2. Antimetabolites
3. Polyglutamation of methotrexate, Is methotrexate a pro-drug?
4. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: A metabolic basis for efficacy in rheumatoid arthritis?
5. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates
6. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells
7. Inhibition of phosphoribosyl pyrophosphate amidotransferase for Erlich ascites-tumour cells by thiopurine nucleotides
8. Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages
9. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages
10. Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts
11. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia
12. Aneuploidy and percentage of S-phase cells determined by flow cytometry correlate with cell phenotype in childhood acute leukemia
13. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma
14. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate
15. Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia
16. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia
17. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study
18. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study
19. Purine metabolism in relation to leukemia and lymphoid cell differentiation
20. Purine pathway enzyme abnormalities in acute lymphoblastic leukemia
21. Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: Results of St Jude Total Therapy Study XII
22. Candidate tumor-suppressor genes MTS1 (p161NK4A) and MTS2 (p151NK4B) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias
23. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: Strategies for enzyme-targeted therapy
24. Regulation of de novo purine synthesis in human bone marrow mononuclear cells by hypoxanthine
25. Feedback inhibition of amidophosphoribosyltransferase regulates the rate of cell growth via purine nucleotide, DNA, and protein syntheses
26. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP-malignant cells: Restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis
27. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells
28. Increased methotrexate-induced DNA strand and cytotoxicity following mutational loss of thymidine kinase
29. Chemotherapy in 998 unselected acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM
30. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: Result of an in vitro study